Challenging Results

Category

Remdesivir Use in Multi-National Clinical Trial of Patients with Moderate COVID-19 & Pneumonia: Perplexing Results

Remdesivir is the only therapy in the United States approved, under emergency use status, as a treatment for COVID-19 along with the just announced convalescent plasma. Referred to as not a ‘knockout drug’ by Dr. Anthony Fauci, Director of the National Institutes of...

Roche Confirms Tocilizumab (Actemra®) Failed to Meet Endpoints in the Phase 3 COVACTA Study Involving COVID-19 Associated Pneumonia

TrialSite recently suggested based on unfolding study results that repurposed IL-6 inhibitors, such as Roche’s Actemra®/ReActemtra® (tocilizumab), may not work to treat patients infected with COVID-19. TrialSite pointed to the results of an Italian study as a...

Fujita Health University Favipiravir Trial Evidences no Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?

Fujita Health University concluded a clinical study of the antiviral drug Avigan and report it has failed to demonstrate a clear efficacy in treating SARS-CoV-2 patients in the early stage of the infection. The Japanese university reports that the delta between those...

Australasian Kidney Trials Network Mobilized in Clinical Trial Revealing Allopurinol Should not be Used for Chronic Kidney Disease

Although up to 20% of kidney disease patients may be prescribed a medication known as Allopurinol, unfortunately the results of a major clinical trial led by University of New South Wales (UNSW) and the George Institute for Global Health in collaboration with the...